-
Add to Cart The item has been addedAb176308-10mgConcizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. -
Add to Cart The item has been addedAb176308-1mgConcizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. -
Add to Cart The item has been addedAb176308-5mgConcizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. -
Add to Cart The item has been addedAb170844-100μgCusatuzumab (anti-CD70) is a human αCD70 monoclonal antibody. Cusatuzumab (anti-CD70) shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab (anti-CD70) reduces leukemia stem cells (LSCs) and triggers gene signatures -
Add to Cart The item has been addedAb170844-10mgCusatuzumab (anti-CD70) is a human αCD70 monoclonal antibody. Cusatuzumab (anti-CD70) shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab (anti-CD70) reduces leukemia stem cells (LSCs) and triggers gene signatures -
Add to Cart The item has been addedAb170844-1mgCusatuzumab (anti-CD70) is a human αCD70 monoclonal antibody. Cusatuzumab (anti-CD70) shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab (anti-CD70) reduces leukemia stem cells (LSCs) and triggers gene signatures -
Add to Cart The item has been addedAb170844-5mgCusatuzumab (anti-CD70) is a human αCD70 monoclonal antibody. Cusatuzumab (anti-CD70) shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab (anti-CD70) reduces leukemia stem cells (LSCs) and triggers gene signatures -
Add to Cart The item has been addedAb170892-100μgDaclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. -
Add to Cart The item has been addedAb170892-10mgDaclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. -
Add to Cart The item has been addedAb170892-1mgDaclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. -
Add to Cart The item has been addedAb170892-5mgDaclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. -
Add to Cart The item has been addedAb170888-100μgDatopotamab (anti-TROP2) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan, TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan and
